• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to footer
  • Subscribe
  • facebook
  • instagram
  • RSS
  • RSMUS.com

The Real Economy Blog

Search

  • Economics
  • Technology
  • Consumer
  • Industrials
  • Finance
  • Real Estate
  • Health Care
  • Life Sciences
Home > Coronavirus > Life sciences industry growth was on a strong trajectory. Then the coronavirus pandemic hit.

Life sciences industry growth was on a strong trajectory. Then the coronavirus pandemic hit.

Mar. 31, 2020 by Adam Lohr

  • email
  • Twitter
  • Facebook
  • Linkedin

Strong consumer spending, historically low unemployment and an easing of trade tensions with China initially fueled optimism early in the year for a 2020 bull market. But as the coronavirus pandemic has upended the global economy, uncertainty and disruption have replaced that once sunny outlook, and the life sciences ecosystem is not immune to the fallout.

The life sciences sector has experienced tremendous growth in recent years, but that momentum has significantly slowed amid the pandemic. The outbreak has disrupted much of the anticipated deal flow in the first quarter of the year. However, because of the long development process for innovations in life science, which involves approval by the Food and Drug Administration, we anticipate that investment is experiencing a delay rather than a stall. Several large mergers and initial public offerings have already taken place. With hundreds of billions of dollars of dry powder specifically tagged for life sciences waiting to be deployed, we expect deal flow eventually to return to 2019 levels once markets stabilize, though it’s difficult to predict when that will happen.

Rapidly growing market

At the end of 2019, there were 1,170 publicly traded life sciences companies in the United States, with a combined market capitalization of more than $3 trillion. In 2019, 64 life sciences companies went public and raised a combined $12 billion of capital. As of the end of February 2020 those companies had an average offer-to-date return of 40%. This level of return is matched only by portions of the technology sector, which is part of the reason that investors are increasingly entering the life sciences ecosystem.

Market movers

This growth in the life sciences sector is driven by several interconnected factors:

  • An aging population with greater access to health care presents a larger and more affluent customer base.
  • A shift from the “traditional economy” to the “new economy,” which is based upon highly innovative and technologically advanced processes (sectors including life sciences, technology and financial services).
  • A growing familiarity with the complex and seemingly futuristic advances in medicine such as cloud-connected medical devices, artificial intelligence, machine learning, and gene sequencing and editing.

These changes all contribute to the overall trend of personalized medicine, which will fundamentally change the way patients, providers and developers interact with the life sciences and health care ecosystems. The markets’ acknowledgement of this opportunity is evidenced by the steady shift of public, corporate and private dollars into the life sciences.

Stretched supply chain

As the disease caused by the new coronavirus continues to spread and the supply shock to the global economy persists, there is increasing concern about how the pandemic will affect the availability and quality of drugs and medical equipment.

The disruption could be particularly significant for the supply of active pharmaceutical ingredients, or API, that produce therapeutic effects in drugs, as RSM noted in early March. While the majority of drugs prescribed in the United States are finished and packaged domestically, the past two decades have seen an almost universal outsourcing of API manufacturing to Asia and India, which have a lower cost of production and less restrictive labor and environmental regulations.

As a result, the United States is able to produce only a quarter of global capacity for APIs. On Feb. 27, FDA Commissioner Stephen Hahn said in a statement that the first shortage of a drug as a result of the outbreak had occurred. While the FDA is closely monitoring more than 180 “at-risk” drugs that are vulnerable to supply chain shocks, the potential exposure is raising concerns by the public and policymakers about the structure of U.S. drug supply chains.

Exposure by the numbers (approximate):

  • 80% of all API manufacturers are outside of the United States.
  • 55% of biologics and 30% of medical devices, by dollar value, are imported.
  • 80% of APIs used by commercial sources to produce finished medicines come from China.
  • 90% of the drugs prescribed in America are generics, and of the generics used in the U.S., 40% are imported from India, which in turn acquires approximately 80% of its APIs from China.
  • 97% of all antibiotics in the United States come from China.

Sources for the numbers above: FDA Regulated Products report; testimony from Christopher Priest, deputy assistant director at the U.S. Defense Health Agency; 2019 testimony from Rosemary Gibson, senior adviser at the Hastings Center; 2018 comments from India’s commerce minister Suresh Prabhakar Prabhu; Department of Commerce study on drug supply chain.

  • email
  • Twitter
  • Facebook
  • Linkedin

Related posts

  • Life science graphic
    Better data use has pros and cons for life sciences

    The volume and variety of health care data should expand significantly in 2019. Specifically, we will be monitoring growth in data sources outside those collected from traditional electronic health records, including information gleaned from wearable technology and direct-to-consumer…

  • Coronavirus reveals vulnerability in the life science supply chain

    There is growing concern on how the coronavirus outbreak could affect the life science industry, especially the availability and quality of drugs and medical equipment.

  • Coronavirus pandemic hinders global automotive supply chains

    With the recent passage of “phase one” of a trade agreement between the United States and China and the ratification of the United States-Mexico-Canada Agreement (USMCA), 2020 was supposed to be a transitional year for the global auto…

Filed Under: Coronavirus, Health Care, Life Sciences

About Adam Lohr

Adam is an audit partner and life sciences senior analyst in RSM's cutting-edge industry eminence program. In addition to providing assurance services to his clients, he sits on RSM’s national life science team and leads the San Diego office life science practice.

His senior analyst responsibilities include advising the firm’s life sciences care clients and client servers as they work to navigate the rapidly changing industry environment. Adam regularly writes, presents and advises on capital markets, digital transformation, policy and other issues transforming life sciences. He is an instructor at the regional and national level, and is experienced in the application of ASC 606 revenue recognition for the technology and consumer products industries.

Adam has over 12 years of accounting and finance experience, serving private equity-backed and private closely held companies in the middle market. He specializes in providing financial audit services and helping clients respond to technical, regulatory and economic changes that impact their business.

Primary Sidebar

Read RSM analysts’ industry coverage of coronavirus.

Categories

  • Economics
  • Technology
  • Consumer Products
  • Industrials
  • Financial Services
  • Real Estate
  • Health Care
  • Life Sciences

Recent Health Care articles

This year may be the busiest ever for health care and life sciences deal volume

Jan. 12, 2021

The case for assistance to state and local governments

Jan. 12, 2021

CHART OF THE DAY: As vaccination begins, health care remains underemployed

Jan. 11, 2021

Recent Life Science articles

5 things to know this week in life sciences: Week of Jan. 11

Jan. 15, 2021

This year may be the busiest ever for health care and life sciences deal volume

Jan. 12, 2021

5 things to know this week in life sciences: Week of Jan. 4

Jan. 7, 2021

RSMUS.com links

The Real Economy

Middle Market Business Index

MMBI Special Reports

Footer

  • Facebook
  • Instagram
  • RSS

About The Real Economy Blog

The Real Economy Blog from RSM US LLP was developed to provide timely economic insights about the middle market economy. It is offered as a complement to RSM’s macroeconomic thought leadership, including The Real Economy monthly publication and the proprietary RSM US Middle Market Business Index (MMBI).

© 2021 RSMUS.com | Privacy Policy | Cookie Policy

The Real Economy Blog
  • Economics
  • Technology
  • Consumer
  • Industrials
  • Finance
  • Real Estate
  • Health Care
  • Life Sciences